HLUYY - Lundbeck Seeing Healthy Double-Digit Growth From New Drugs But The Pipeline Is Very Thin
The COVID-19 pandemic has created many challenges across the healthcare sector, but it has been even a little more challenging for H. Lundbeck (OTCPK:HLUYY) as the CNS drugs that make up Lundbeck’s focus are more sensitive to in-patient visits. Still, the company has executed reasonably well, with better than expected progress on cost-cutting.
As has been the case for some time, the pipeline is the main sticking point. Another clinical failure of a once-promising asset means no novel compounds in Phase II or Phase III testing, and the jury is still very much